MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jns.2024.123052

Медицинская библиотека · Journal of the neurological sciences · 2024

Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.

Piedrabuena Maria A, Correale Jorge, Fiol Marcela, Marrodan Mariano, Rojas Juan I, Alonso Marina, Pappolla Agustín, Miguez Jimena, Patrucco Liliana, Cristiano Edgardo, Vrech Carlos, Cohen Leila, Alonso Ricardo, Silva Berenice, Luetic Geraldine, Deri Norma, Burgos Marcos, Liwacki Susana, Piedrabuena Raul, Tkachuk Verónica, Barboza Andres, Martinez Alejandra, Balbuena Maria E, Pinheiro Amelia Alves, Nofal Pedro, Lopez Pablo A, Tavolini Dario, Leguizamon Felisa, Hryb Javier P, Tizio Santiago, Recchia Luciano, Reich Edgardo, Contentti Edgar Carnero, Marcilla Marcela Parada, Pagani Fatima, Cabrera Lorena M, Curbelo Maria C, Mainella Carolina, Liguori Nora Fernández, Coppola Mariano, Pettinicchi Juan P, Carra Adriana, Jose Gustavo, Nadur Debora, Bestoso Santiago, Pestchanker Claudia, Vazquez Guido D, Martinez Carlos M, Ysrraelit María C

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is to evaluate the choice of DMTs in pwMS older than 50 years old in a real-world setting.

METHODS

Cross-sectional study of pwMS from the Argentine MS and NMOSD Registry. We included patients under 35 and above 50 years old prescribed DMTs. Disease activity was categorized as highly active (HA) or not highly active (NHA), and DMTs were classified as low efficacy therapies (LET) or high efficacy therapies (HET).

RESULTS

1460 patients (65% females) were enrolled. The HA group comprised 241 patients, 198 young (82.2%) and 43 older (17.8%). The NHA group included 1219 patients, 893 young (73%) and 326 older (27%). In the NHA group, older patients received LET more frequently than younger patients (66% versus 44%; p < 0.01). In the HA group, older patients received LET in 61% of cases, whereas younger patients received HET in 71% (p = 0.01).

CONCLUSION

The study shows the preference of LET in older patients regardless of disease activity. However it does not demonstrate a difference in disability in older patients based on low vs high efficacy DMTs used, probably due to the design of the study. Further longitudinal studies are warranted to address this issue.

Для цитирования: Piedrabuena Maria A, Correale Jorge, Fiol Marcela, Marrodan Mariano, Rojas Juan I, Alonso Marina, Pappolla Agustín, Miguez Jimena, Patrucco Liliana, Cristiano Edgardo, Vrech Carlos, Cohen Leila, Alonso Ricardo, Silva Berenice, Luetic Geraldine, Deri Norma, Burgos Marcos, Liwacki Susana, Piedrabuena Raul, Tkachuk Verónica, Barboza Andres, Martinez Alejandra, Balbuena Maria E, Pinheiro Amelia Alves, Nofal Pedro, Lopez Pablo A, Tavolini Dario, Leguizamon Felisa, Hryb Javier P, Tizio Santiago, Recchia Luciano, Reich Edgardo, Contentti Edgar Carnero, Marcilla Marcela Parada, Pagani Fatima, Cabrera Lorena M, Curbelo Maria C, Mainella Carolina, Liguori Nora Fernández, Coppola Mariano, Pettinicchi Juan P, Carra Adriana, Jose Gustavo, Nadur Debora, Bestoso Santiago, Pestchanker Claudia, Vazquez Guido D, Martinez Carlos M, Ysrraelit María C. Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.. Journal of the neurological sciences. 2024. DOI: 10.1016/j.jns.2024.123052.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.